

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CStone Pharmaceuticals**  
**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2616)**

**POLL RESULTS OF ANNUAL GENERAL MEETING  
HELD ON JUNE 18, 2024  
AND  
AMENDMENTS TO THE ARTICLES OF  
ASSOCIATION**

**POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 18, 2024**

Reference is made to the notice of annual general meeting (the “**AGM Notice**”) of CStone Pharmaceuticals (the “**Company**”) dated May 27, 2024. The board of directors (the “**Board**”) of the Company is pleased to announce that all the resolutions (the “**Resolutions**”) set out in the AGM Notice were duly passed by the shareholders (the “**Shareholders**”) of the Company as ordinary resolutions or special resolution by way of poll at the annual general meeting of the Company held on June 18, 2024 (the “**AGM**”).

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors of the Company (“ <b>Directors</b> ”) and auditors for the year ended December 31, 2023	283,103,076 (100.000000%)	0 (0.000000%)	283,103,076 (100.000000%)
2.	(i) To re-elect Mr. Kenneth Walton Hitchner III as a non-executive Director	282,680,615 (99.850775%)	422,461 (0.149225%)	283,103,076 (100.000000%)
	(ii) To re-elect Mr. Edward Hu as a non-executive Director	282,680,615 (99.850775%)	422,461 (0.149225%)	283,103,076 (100.000000%)
	(iii) To re-elect Mr. Ting Yuk Anthony Wu as an independent non-executive Director	235,621,643 (83.228217%)	47,481,433 (16.771783%)	283,103,076 (100.000000%)

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
3.	To authorise the board of Directors to fix the remuneration of the Directors	283,103,076 (100.000000%)	0 (0.000000%)	283,103,076 (100.000000%)
4.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the board of Directors to fix their remuneration	283,103,076 (100.000000%)	0 (0.000000%)	283,103,076 (100.000000%)
5.	To grant a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company (excluding any treasury shares of the Company)	237,901,643 (84.033578%)	45,201,433 (15.966422%)	283,103,076 (100.000000%)
6.	To grant a general mandate to the Directors to buy back shares not exceeding 10% of the issued share capital of the Company (excluding any treasury shares of the Company)	283,103,076 (100.000000%)	0 (0.000000%)	283,103,076 (100.000000%)
7.	To extend the authority given to the Directors pursuant to ordinary resolution no. 5 to issue shares by adding to the issued share capital of the Company the number of shares bought back under ordinary resolution no. 6	237,901,643 (84.033578%)	45,201,433 (15.966422%)	283,103,076 (100.000000%)
8.	To consider and approve the grant of 1,890,000 Share Options and 1,890,000 RSUs to Dr. Jianxin Yang, an executive director and the chief executive officer of the Company	95,719,656 (68.399213%)	44,222,972 (31.600787%)	139,942,628 (100.000000%)

Special Resolution		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
9.	To consider and approve that the memorandum and articles of association of the Company (the “ <b>Articles of Association</b> ”) currently in effect be amended and restated by the deletion in their entirety and the amended and restated Articles of Association (the “ <b>New Articles of Association</b> ”) be approved and adopted in substitution for and to the exclusion of the Articles of Association with immediate effect after the close of the meeting; and any one director and/or the registered office provider of the Company be and is hereby authorised severally to do all things necessary or expedient to implement the adoption of the New Articles of Association, including without limitation, attending to the necessary filings in accordance with the relevant requirements of the applicable laws, rules and regulations in the Cayman Islands and Hong Kong	283,103,076 (100.000000%)	0 (0.000000%)	283,103,076 (100.000000%)

*Notes:*

1. As more than 50% of the votes were cast in favour of each of the Resolutions numbered 1 to 8, the Resolutions numbered 1 to 8 proposed at the AGM were duly passed as ordinary resolutions of the Company.
2. As not less than three-fourths of votes were cast in favour of the Resolution numbered 9, the Resolution numbered 9 proposed at the AGM was duly passed as special resolution of the Company.
3. The full text of the Resolutions is set out in the AGM Notice.
4. As at the date of the AGM, (i) the total number of ordinary shares of the Company (the “**Shares**”) in issue was 1,284,191,212 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions numbered 1 to 7 and 9 proposed at the AGM; and (ii) the Company did not hold any treasury shares (which shall have the meaning ascribed to it under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Dr. Jianxin Yang, his associates and all core connected persons of the Company, directly and indirectly, holding an aggregate of 453,307,638 Shares, representing approximately 35.30% of the total issued share capital of the Company as at the date of the AGM, were required to abstain from voting on the Resolution numbered 8 proposed at the AGM. The total Shares entitling the Shareholders to attend and vote on the Resolution numbered 8 proposed at the AGM were 830,883,574 Shares.

Save as disclosed above, to the best of the knowledge, information and belief of the board of Directors, and having made all reasonable enquiries:

- (i) there were no Shareholders who were entitled to attend the AGM but was required to abstain from voting in favor of the Resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules;
  - (ii) none of the Shareholders was required under the Listing Rules to abstain from voting on any of the Resolutions proposed at the AGM; and
  - (iii) there was no restriction on any Shareholders to cast votes on any of the Resolutions proposed at the AGM and none of the Shareholders have stated their intention in the circular of the Company dated May 27, 2024 to vote against or to abstain from voting on any of the Resolutions at the AGM.
5. Computershare Hong Kong Investor Services Limited, the Company's Hong Kong share registrar, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.
  6. The following Directors attended the AGM: Dr. Wei Li, Dr. Jianxin Yang, Mr. Xianghong Lin, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun. Mr. Kenneth Walton Hitchner III, Mr. Edward Hu and Dr. Paul Herbert Chew were unable to attend the AGM due to other business commitment.

## **AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The Board is pleased to announce that pursuant to the above special resolution numbered 9, the Articles of Association has been amended and restated pursuant to the proposed amendments with effect from June 18, 2024. Please refer to the circular of the Company dated May 27, 2024 for details of the proposed amendments. For the full text of the amended and restated Articles of Association of the Company, please refer to the websites of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.cstonepharma.com](http://www.cstonepharma.com)).

By Order of the Board  
**CStone Pharmaceuticals**  
**Dr. Wei Li**  
*Chairman*

Hong Kong, June 18, 2024

*As at the date of this announcement, the Board of Directors comprises Dr. Wei Li as Chairman and non-executive Director, Dr. Jianxin Yang as executive Director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.*